INKON Life(SZ:300143)2022-12-06 11:28Group 1: Company Overview and Transformation - The company, Guangdong Xinghe Biological Technology Co., Ltd., successfully transformed into the health care industry after acquiring 100% of Maxip in 2015, following two consecutive years of losses in the edible mushroom sector [3]. - In 2015, the company turned a profit without consolidating Maxip's earnings, alleviating the risk of delisting; the net profit for Q1 2016 was approximately 8.14 million [3]. Group 2: Future Development Plans - The company plans to expand in the medical health industry, focusing on high-end medical equipment and maintaining attention on new technologies related to Maxip's business [3][4]. - In the medical services sector, the company aims to enrich its business model and profit structure by potentially acquiring or collaborating on high-quality assets such as gamma knife treatment centers and specialized hospitals [4]. Group 3: Product and Market Insights - The company has 18 orders for Maxip products, including 7 first-generation gamma knives, 5 body gamma knives, and 6 second-generation gamma knives [4]. - The cobalt source is expected to be released between late May and early June [4]. Group 4: Financial Performance and Projections - In 2015, revenue from cobalt source replacement was approximately 12.8 million, while income from equipment upgrades and maintenance was around 10.1 million [5]. - The cost for replacing the cobalt source after 6-7 years is estimated at 3.3 million [5]. Group 5: Regulatory and Market Impact - The company’s gamma knife products are not subject to the health commission's configuration certificate indicators, allowing for greater flexibility in deployment [4][5]. - The recent Wei Zexi incident serves as a warning but is not expected to negatively impact the company; instead, it may lead to positive outcomes following regulatory adjustments [6].